EVMN
EVMNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePart of the healthcare sector, EVMN (EVMN) is listed under Biotechnology. The company carries a $445.3M market cap, placing it firmly in the small-cap category. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis.
Market Cap
$445.3M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-3.61
EPS (TTM)
$-11.82
EPS (Fwd)
$-3.40
ROE
-52.1%
ROA
-32.0%
Cash
$200.8M
Total Debt
$8.6M
Free CF
-$39.1M
52W Change
-39.4%
Annual Financials
Cash vs Debt
Where EVMN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, EVMN finished 38.85% below its 150-day moving average ($20.41) and 37.57% below its 200-day moving average ($19.99). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EVMN overbought or oversold?
At the September 3, 2026 close, EVMN's RSI(14) was 37.0, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
EVMN holds $200.8M in cash against $8.6M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$39.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -52.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for EVMN and its sector.